CN114341120A - Abcc11抑制剂 - Google Patents

Abcc11抑制剂 Download PDF

Info

Publication number
CN114341120A
CN114341120A CN202080058788.5A CN202080058788A CN114341120A CN 114341120 A CN114341120 A CN 114341120A CN 202080058788 A CN202080058788 A CN 202080058788A CN 114341120 A CN114341120 A CN 114341120A
Authority
CN
China
Prior art keywords
inhibitor
abcc11
group
linear
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058788.5A
Other languages
English (en)
Chinese (zh)
Inventor
豊田优
高田龙平
铃木洋史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of CN114341120A publication Critical patent/CN114341120A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN202080058788.5A 2019-08-21 2020-08-21 Abcc11抑制剂 Pending CN114341120A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890053P 2019-08-21 2019-08-21
US62/890,053 2019-08-21
PCT/JP2020/031672 WO2021033773A1 (ja) 2019-08-21 2020-08-21 Ａｂｃｃ１１阻害剤

Publications (1)

Publication Number Publication Date
CN114341120A true CN114341120A (zh) 2022-04-12

Family

ID=74659662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058788.5A Pending CN114341120A (zh) 2019-08-21 2020-08-21 Abcc11抑制剂

Country Status (5)

Country Link
US (1) US20220288038A1 (https=)
EP (1) EP4019048A4 (https=)
JP (1) JP7440934B2 (https=)
CN (1) CN114341120A (https=)
WO (1) WO2021033773A1 (https=)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206937A1 (en) * 1999-07-16 2002-05-22 Shoei Co., Ltd. Nitroimidazole external preparations for dermatosis
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
US20070212366A1 (en) * 2003-11-07 2007-09-13 Ernst-Moritz-Arndt-Universitat Greifswald Use Of Mrp4-Inhibitors For The Treatment And/Or Prophylaxis Of Cardiovascular Diseases
CN101505755A (zh) * 2006-06-22 2009-08-12 日本化学医药株式会社 抗癌药耐性克服剂
WO2009138156A1 (de) * 2008-05-15 2009-11-19 Beiersdorf Ag Kosmetische zubereitungen zur verminderung von schweissgeruch mit abcc-modulatoren
CN102093309A (zh) * 2006-12-07 2011-06-15 重庆医药工业研究院有限责任公司 非布司他的新晶型及其制备方法
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
US20130178484A1 (en) * 2010-06-15 2013-07-11 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
CN105399694A (zh) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体
CN105949156A (zh) * 2016-05-15 2016-09-21 刘雨 一种伊曲康唑的药物组合物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
KR20190123256A (ko) 2016-07-29 2019-10-31 로저 엘. 카스파 액취증 치료 방법

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206937A1 (en) * 1999-07-16 2002-05-22 Shoei Co., Ltd. Nitroimidazole external preparations for dermatosis
CN1361688A (zh) * 1999-07-16 2002-07-31 昭荣株式会社 含有硝基咪唑的皮肤病外用药
US20070212366A1 (en) * 2003-11-07 2007-09-13 Ernst-Moritz-Arndt-Universitat Greifswald Use Of Mrp4-Inhibitors For The Treatment And/Or Prophylaxis Of Cardiovascular Diseases
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
CN101505755A (zh) * 2006-06-22 2009-08-12 日本化学医药株式会社 抗癌药耐性克服剂
US20100234399A1 (en) * 2006-06-22 2010-09-16 Nippon Chemiphar Co., Ltd. Agent for overcoming resistance to anti-cancer agent
CN102093309A (zh) * 2006-12-07 2011-06-15 重庆医药工业研究院有限责任公司 非布司他的新晶型及其制备方法
WO2009138156A1 (de) * 2008-05-15 2009-11-19 Beiersdorf Ag Kosmetische zubereitungen zur verminderung von schweissgeruch mit abcc-modulatoren
US20130178484A1 (en) * 2010-06-15 2013-07-11 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
CN105399694A (zh) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体
CN105949156A (zh) * 2016-05-15 2016-09-21 刘雨 一种伊曲康唑的药物组合物及其医药用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AAK EL-SHEIKH等: "Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4", 《BRITISH JOURNAL OF PHARMACOLOGY》, vol. 155, no. 2008, 25 August 2008 (2008-08-25), pages 1066 - 1075 *
ZANCONG SHEN等: "In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters", 《CLIN DRUG INVESTIG.》, vol. 36, no. 2016, 7 March 2016 (2016-03-07), pages 443 - 452 *
周启蒙;杜冠华;: "治疗高尿酸血症相关药物研究进展", 中国新药杂志, no. 18, 31 December 2016 (2016-12-31), pages 2129 - 2135 *

Also Published As

Publication number Publication date
JPWO2021033773A1 (https=) 2021-02-25
US20220288038A1 (en) 2022-09-15
EP4019048A4 (en) 2023-10-04
WO2021033773A1 (ja) 2021-02-25
EP4019048A1 (en) 2022-06-29
JP7440934B2 (ja) 2024-02-29

Similar Documents

Publication Publication Date Title
Olesen et al. Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases
Chen et al. Steady augmentation of anti-osteoarthritic actions of rapamycin by liposome-encapsulation in collaboration with low-intensity pulsed ultrasound
Chiara et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels
Ishihara et al. Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor
KR20080012339A (ko) 과증식성 상피 질환 치료 조성물 및 방법
CN104471391B (zh) 鉴别具有治疗性皮脂抑制活性的ahr受体的配体的方法以及所述配体
Morgan et al. A role for Cav1. 3 in rat intestinal calcium absorption
Lee et al. PDK2 deficiency prevents ovariectomy‐induced bone loss in mice by regulating the RANKL‐NFATc1 pathway during osteoclastogenesis
JP2016523960A (ja) 限局性強皮症の膏薬療法
Sato et al. Glucocorticoid-induced bone fragility is prevented in female mice by blocking Pyk2/Anoikis signaling
Dick et al. Estrogen and androgen regulation of plasma membrane calcium pump activity in immortalized distal tubule kidney cells
TW590775B (en) Pharmaceutical compositions for increasing or decreasing phagocytosis in mammalian cells
US8431617B2 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
Sidorenko et al. Antioxidant mito-TEMPO prevents the increase in tropomyosin oxidation and mitochondrial calcium accumulation under 7-day rat hindlimb suspension
EP4572737A1 (en) Methods of using a small molecule chemical compound to reduce the appearance of rhytids and wrinkles
Xu et al. A short report: PAMM, a novel antioxidant protein, induced by oxidative stress
CN114341120A (zh) Abcc11抑制剂
WO2020210642A1 (en) Methods and compositions for treating urea cycle disorders
JP6785248B2 (ja) 肝硬変に罹患した患者における細菌感染症の処置のための方法及び医薬組成物
Zhou et al. Effects of natural 24-epibrassinolide on inducing apoptosis and restricting metabolism in hepatocarcinoma cells
US6706691B1 (en) Immunosupportive drug sparing diet
WO2002045704A2 (en) Prevention and treatment of tachyphylactic response
US11680264B2 (en) Methods of modulating melanosome pH and melanin level in cells
Han et al. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease
Lee et al. Highly solubilized and skin-permeable finasteride formulation using HPCD-incorporated chitosan nanocapsules to promote hair regeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220412

WD01 Invention patent application deemed withdrawn after publication